ELI LILLY & Co
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Eli Lilly and Company
| By | /s/ David Ricks |
|---|---|
| David Ricks | |
| Chair, President, and Chief Executive Officer | |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February 21, 2024 by the following persons on behalf of the Registrant and in the capacities indicated.
| Signature | Title |
|---|---|
| /s/ David Ricks | Chair, President, and Chief Executive Officer (principal executive officer) |
| DAVID RICKS | |
| /s/ Anat Ashkenazi | Executive Vice President and Chief Financial Officer (principal financial officer) |
| ANAT ASHKENAZI | |
| /s/ Donald Zakrowski | Senior Vice President, Finance, and Chief Accounting Officer (principal accounting officer) |
| DONALD ZAKROWSKI | |
| /s/ Ralph Alvarez | Director |
| RALPH ALVAREZ | |
| /s/ Katherine Baicker, Ph.D. | Director |
| KATHERINE BAICKER, Ph.D. | |
| /s/ Erik Fyrwald | Director |
| ERIK FYRWALD | |
| /s/ Mary Lynne Hedley, Ph.D. | Director |
| MARY LYNNE HEDLEY, Ph. D. | |
| /s/ Jamere Jackson | Director |
| JAMERE JACKSON | |
| /s/ Kimberly Johnson | Director |
| KIMBERLY JOHNSON | |
| /s/ William Kaelin, Jr., M.D. | Director |
| WILLIAM KAELIN, JR., M.D. | |
| /s/ Juan Luciano | Director |
| JUAN LUCIANO | |
| /s/ Marschall Runge, M.D., Ph.D. | Director |
| MARSCHALL RUNGE, M.D., Ph.D. | |
| /s/ Gabrielle Sulzberger | Director |
| GABRIELLE SULZBERGER | |
| /s/ Karen Walker | Director |
| KAREN WALKER | |
Trademarks Used In this Annual Report on Form 10-K
Trademarks or service marks owned by Eli Lilly and Company or its affiliates, when first used in each item of this Annual Report on Form 10-K, appear with an initial capital and are followed by the symbol® or™, as applicable. In subsequent uses of the marks in the item, the symbols may be omitted.
Actos® is a registered trademark of Takeda Pharmaceutical Company Limited.
Baqsimi® is a registered trademark of Amphastar Pharmaceuticals, Inc.
Glyxambi®, Jardiance®, Jentadueto®, Synjardy®, Trajenta®, and Trijardy® are trademarks of Boehringer Ingelheim International GmbH.
Tyvyt® is a registered trademark of Innovent Biologics (Suzhou) Co., Ltd.
Qbrexza® is a registered trademark of Journey Medical Corporation.
Zyprexa® is a registered trademark of Cheplapharm Arzneimittel GmbH.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.